Loading...
AMED logo

Amedisys, Inc.NasdaqGS:AMED Stok Raporu

Piyasa Değeri US$3.3b
Hisse Fiyatı
US$100.99
US$96.17
5.0% aşırı değerlenmiş içsel indirim
1Y2.6%
7D0.1%
1D
Portföy Değeri
​
Görünüm

Amedisys, Inc.

NasdaqGS:AMED Stok Raporu

Piyasa değeri: US$3.3b

This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

Amedisys (AMED) Hisse Özeti

Amedisys, Inc. iştirakleri ile birlikte Amerika Birleşik Devletleri'nde sağlık hizmetleri sunmaktadır. Daha fazla detay

Ödüller

Adil değer tahminimizden 41.8% daha düşük bir oranda işlem görüyor

Kazançların yılda 41.08% oranında artması öngörülüyor

Risk Analizi

Finansal sonuçları etkileyen büyük tek seferlik kalemler


AMED Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

View all narratives

Amedisys, Inc. Rakipler

Fiyat Geçmişi ve Performans

Hisse fiyatlarındaki yükseliş, düşüş ve değişimlerin özeti Amedisys
Tarihsel hisse senedi fiyatları
Güncel Hisse FiyatıUS$100.99
52 Haftanın En Yüksek SeviyesiUS$101.02
52 Haftanın En Düşük SeviyesiUS$82.15
Beta0.90
1 Aylık Değişim3.57%
3 Aylık Değişim6.73%
1 Yıllık Değişim2.58%
3 Yıllık Değişim-16.02%
5 Yıllık Değişim-57.69%
Halka arzdan bu yana değişim1,823.61%

Son Haberler & Güncellemeler

Analiz Makalesi • Aug 14

Why Amedisys, Inc. (NASDAQ:AMED) Could Be Worth Watching

While Amedisys, Inc. ( NASDAQ:AMED ) might not have the largest market cap around , it maintained its current share...
Seeking Alpha • Aug 04

Amedisys: Thoughts On UnitedHealth Merger, Plus Underlying Factors

Summary AMED's planned merger with UnitedHealth remains on the rocks, with regulatory overhang still an issue. The deal is also asymmetrically weighted in UNH's favor, with the latter up for no penalty if it fails. Not so for AMED. Aside from this, there are internal factors dragging on AMED's business performance. Read the full article on Seeking Alpha
Analiz Makalesi • Jun 11

There's Reason For Concern Over Amedisys, Inc.'s (NASDAQ:AMED) Price

There wouldn't be many who think Amedisys, Inc.'s ( NASDAQ:AMED ) price-to-sales (or "P/S") ratio of 1.3x is worth a...

Recent updates

Analiz Makalesi • Aug 14

Why Amedisys, Inc. (NASDAQ:AMED) Could Be Worth Watching

While Amedisys, Inc. ( NASDAQ:AMED ) might not have the largest market cap around , it maintained its current share...
Seeking Alpha • Aug 04

Amedisys: Thoughts On UnitedHealth Merger, Plus Underlying Factors

Summary AMED's planned merger with UnitedHealth remains on the rocks, with regulatory overhang still an issue. The deal is also asymmetrically weighted in UNH's favor, with the latter up for no penalty if it fails. Not so for AMED. Aside from this, there are internal factors dragging on AMED's business performance. Read the full article on Seeking Alpha
Analiz Makalesi • Jun 11

There's Reason For Concern Over Amedisys, Inc.'s (NASDAQ:AMED) Price

There wouldn't be many who think Amedisys, Inc.'s ( NASDAQ:AMED ) price-to-sales (or "P/S") ratio of 1.3x is worth a...
Seeking Alpha • Nov 05

Final Push For Amedisys As UnitedHealth Awaits Regulatory Clearance

Summary Amedisys, Inc. is being acquired by UnitedHealth for $3.3 billion, pending DOJ approval, with the stock currently trading below the offer price. The DOJ is scrutinizing the merger due to concerns about potential price hikes and reduced competition in home healthcare. Oregon Health Authority is also reviewing the deal, with mixed reactions from local groups about its impact on healthcare quality and affordability. If the merger fails, Amedisys stock could drop to $74, but a $144 million break-up fee from UnitedHealth offers some downside protection. Read the full article on Seeking Alpha
Analiz Makalesi • Apr 10

Is Amedisys, Inc. (NASDAQ:AMED) Trading At A 41% Discount?

Key Insights Amedisys' estimated fair value is US$130 based on 2 Stage Free Cash Flow to Equity Amedisys' US$76.89...
Analiz Makalesi • Feb 25

Does Amedisys (NASDAQ:AMED) Have A Healthy Balance Sheet?

Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
Analiz Makalesi • Feb 10

Amedisys (NASDAQ:AMED) Will Be Hoping To Turn Its Returns On Capital Around

If you're not sure where to start when looking for the next multi-bagger, there are a few key trends you should keep an...
Analiz Makalesi • Jan 03

At US$83.54, Is It Time To Put Amedisys, Inc. (NASDAQ:AMED) On Your Watch List?

Amedisys, Inc. ( NASDAQ:AMED ), might not be a large cap stock, but it saw significant share price movement during...
Analiz Makalesi • Dec 16

A Look At The Fair Value Of Amedisys, Inc. (NASDAQ:AMED)

Today we'll do a simple run through of a valuation method used to estimate the attractiveness of Amedisys, Inc...
Analiz Makalesi • Nov 12

Capital Allocation Trends At Amedisys (NASDAQ:AMED) Aren't Ideal

What trends should we look for it we want to identify stocks that can multiply in value over the long term? Firstly...
Analiz Makalesi • Sep 19

Is Now The Time To Look At Buying Amedisys, Inc. (NASDAQ:AMED)?

Amedisys, Inc. ( NASDAQ:AMED ), might not be a large cap stock, but it saw a decent share price growth in the teens...
Analiz Makalesi • Sep 04

An Intrinsic Calculation For Amedisys, Inc. (NASDAQ:AMED) Suggests It's 38% Undervalued

Today we will run through one way of estimating the intrinsic value of Amedisys, Inc. ( NASDAQ:AMED ) by taking the...
Seeking Alpha • Aug 24

Amedisys: ROIC, Tangible Book Value Each Softening

Summary Amedysis came in with a flat set of earnings last quarter, with downsides relative to consensus at the top and bottom line. Balance sheet metrics are weakening and the company now claims a large portion of equity value via intangibles and goodwill. We note additional pressures from return on investment that's been observed over several periods now. Valuations are also unsupportive, and we rate AMED neutral. Investment Summary Risk assets have caught a bid since July and are now rallying to retrace losses incurred in early 2022. Within healthcare, there are numerous pockets of quality screaming out for capital allocation. Most notably, characteristics of free cash flow ("FCF"), tangible book value, and earnings quality are paramount. Exhibit 1. AMED YTD price performance Data: Updata In that vein, we note that Amedysis, Inc. (AMED) displays a loose affinity to the equity premia we are seeking exposure to in H2 FY22. On closer inspection, the balance sheet is skewed towards intangible sources of value that are susceptible to mark downs and don't provide certainty on the predictability of future cash flows. Valuations are also unsupportive. With these factors in mind, we rate AMED neutral. Q2 earnings flat, insights for FY22 result Q2 revenue came in with a 100bps decline to $558 million, below consensus estimates and behind guidance. Home Health turnover came in at ~$350 million, with a ~400bps impact from Q2 acquisitions. More on this a bit later. Structurally, the home health business now books 20% of revenue from a per-visit basis. This equates to ~200K/month of ~600K/quarter. However, management says it is moving towards a blend where more revenue upside is recognized on a per-case basis (instead of per visit). This has potential to unlock scale in the segment because it frees up more clinical capacity for greater patient uptake. Meanwhile, the hospice segment printed $198 million for the quarter, backed by a 400bps YoY increase in net revenue per day, offset by a $2.88 cost per day. The company also realized a 200bps pass-through in hospice rate increase that's been in effect since 1 October FY21'. Moving down the P&L, the company saw ~125bps of headwind at the SG&A line thanks to acquisition costs tied to Contessa and Home Health. Non-GAAP EBITDA was up 150bps YoY to $182 million ($5.60/share), whereas it printed GAAP EBITDA of $42 million ($1.31/share). In addition, AMED recognized ~200bps upside in revenue per episode, helped in part by a similar increase in reimbursement. There was also a 6% increase in visiting cost per visit, underpinned by higher cost inflation, labour shortages and increase salaried employments. As seen in Exhibit 2, quarterly operating performance has begun to slow markedly for the company since FY19. Despite a small spike in sales and gross profit in FY20, this growth has stagnated and even receded back in range. Despite this, the company remains FCF positive and exhibits a sense of resiliency in its earnings profile. It printed $55 million in FCF last quarter, a YoY gain of 5.7% from $52.3 million. Although, total debt also increased by 146% YoY and ~3% sequentially to $442 million. The company also spent $17 million during the year on stock buybacks, with another $83 million under authorization. Exhibit 2. Data: HB Insights Estimates; AMED SEC Filings Further evidence of this separation in top-to-bottom line fundamentals is seen in the chart below. As seen, FCF margin (as a function of turnover) and gross profit margin have begun to bifurcate since mid-2020. Operating margin has followed suit since Q3 FY21'. As seen below, the trends have continued to widen and we estimate this to be a potential risk to earnings growth looking ahead. We also advocate for investors to pay close attention to movement in AMED's operating and FCF margins as a measure of earnings performance. Exhibit 3. Data: HB Insights, AMED SEC Filings Additional balance sheet forensics reveal that tangible equity value has narrowed on a quarterly basis since FY18. As seen in Exhibit 4, the company's asset structure has shifted towards an intangibles/goodwill bias, with approximately 70% of the company's asset base now comprised of non-tangible sources of value. This has direct implications on valuation, and, also, as a measure of management's effectiveness in its acquisition strategy. The company continues to build the breadth of its portfolio companies, however, questions arise on the fair value of these purchases considering the total in goodwill that's tied to each. Exhibit 4. Image: HB Insights, AMED SEC Filings As seen in Exhibit 5, taken from AMED's Q2 FY22 10-Q earnings report, goodwill and intangibles make up more than 130% of the company's book value of equity. That means that tangible assets make up just 0.89% of book value. Moreover, patient accounts receivable comprises over 77% of the company's current assets. Exhibit 5. Data: AMED 10-Q, July FY2022 With an arguable lack of tangible value on offer, return on invested capital has narrowed in substantially as well. As seen below, we examined how much NOPAT was derived from the previous period's invested capital. After some growth throughout the pandemic, both NOPAT and ROIC have receded and are now trending south. Exhibit 6. Data: HB Insights, AMED SEC Filings Valuation Shares are trading at a discount to peers across key multiples used in this assessment. As noted, the company trades at ~4x book value, however, a large portion of its book value is made of intangibles and goodwill. AMED actually has a tangible book value of negative $410 million, and therefore struggles to justify this discount. Moreover, the stock is priced at 17.6x forward P/E, below the GICS industry peer median's 21.4x, suggesting the market is pricing a below-sector result from the company. Exhibit 7. Multiples and comps Data: HB Insights At 17.6x our FY23 estimates of $5.80, we price the stock at $102, suggesting there to be a lack of upside capture available on terms of valuation.
Analiz Makalesi • Aug 04

Slowing Rates Of Return At Amedisys (NASDAQ:AMED) Leave Little Room For Excitement

What trends should we look for it we want to identify stocks that can multiply in value over the long term? One common...
Seeking Alpha • Jul 27

Amedisys profit beats by $0.24, revenue misses by $25.23M, 2022 guidance below estimates

Amedisys  press release (NASDAQ:AMED): Q2 Non-GAAP EPS of $1.47 beats by $0.24. Revenue of $557.89M (-1.1% Y/Y) misses by $25.23M. Updated 2022 Guidance Adjusted net service revenue is anticipated to be in the range of $2.290 billion to $2.310 billion vs $2.35B consensus. Adjusted diluted earnings per share is anticipated to be in the range of $5.23 to $5.45 based on an estimated 32.8 million shares outstanding. Consensus estimate $5.31.
Analiz Makalesi • Jul 20

We Think Amedisys (NASDAQ:AMED) Can Stay On Top Of Its Debt

Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
Analiz Makalesi • Jun 04

At US$115, Is It Time To Put Amedisys, Inc. (NASDAQ:AMED) On Your Watch List?

Amedisys, Inc. ( NASDAQ:AMED ), is not the largest company out there, but it saw significant share price movement...
Analiz Makalesi • May 05

Returns On Capital At Amedisys (NASDAQ:AMED) Have Stalled

There are a few key trends to look for if we want to identify the next multi-bagger. Firstly, we'd want to identify a...
Analiz Makalesi • Apr 20

Is Amedisys, Inc. (NASDAQ:AMED) Trading At A 40% Discount?

Does the April share price for Amedisys, Inc. ( NASDAQ:AMED ) reflect what it's really worth? Today, we will estimate...
Analiz Makalesi • Apr 06

Does Amedisys (NASDAQ:AMED) Deserve A Spot On Your Watchlist?

Like a puppy chasing its tail, some new investors often chase 'the next big thing', even if that means buying 'story...
Analiz Makalesi • Feb 20

Is Amedisys (NASDAQ:AMED) A Risky Investment?

Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
Analiz Makalesi • Jan 19

Amedisys (NASDAQ:AMED) Shareholders Will Want The ROCE Trajectory To Continue

If you're looking for a multi-bagger, there's a few things to keep an eye out for. Firstly, we'd want to identify a...
Analiz Makalesi • Dec 03

Should You Be Adding Amedisys (NASDAQ:AMED) To Your Watchlist Today?

For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...
Analiz Makalesi • Nov 18

These 4 Measures Indicate That Amedisys (NASDAQ:AMED) Is Using Debt Safely

David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
Analiz Makalesi • Aug 18

Amedisys (NASDAQ:AMED) Could Easily Take On More Debt

The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
Analiz Makalesi • Jul 23

Calculating The Fair Value Of Amedisys, Inc. (NASDAQ:AMED)

Today we will run through one way of estimating the intrinsic value of Amedisys, Inc. ( NASDAQ:AMED ) by projecting its...
Seeking Alpha • Jul 18

Amedisys: Strategic Contessa Acquisition Underpins The Home Healthcare Growth Opportunity

Amedisys announces the acquisition of Contessa Health, a leader in hospital-at-home services. Despite the near-term margin drag, the added growth potential and strategic benefits should drive upside to the longer-term earnings trajectory. Shares continue to trade reasonably relative to the growth outlook.

Hissedar Getirileri

AMEDUS HealthcareUS Pazar
7D0.1%-1.3%1.5%
1Y2.6%12.4%28.6%

Getiri vs. Endüstri: AMED geçen yıl % 12.4 oranında getiri sağlayan US Healthcare sektörünü aştı.

Getiri vs Piyasa: AMED geçen yıl % 28.6 oranında getiri sağlayan US Piyasasının altında performans gösterdi.

Fiyat Oynaklığı

Is AMED's price volatile compared to industry and market?
AMED volatility
AMED Average Weekly Movement1.5%
Healthcare Industry Average Movement7.3%
Market Average Movement7.2%
10% most volatile stocks in US Market16.8%
10% least volatile stocks in US Market3.0%

İstikrarlı Hisse Senedi Fiyatı: AMED son 3 ayda US piyasasına kıyasla önemli bir fiyat oynaklığı yaşamadı.

Zaman İçindeki Volatilite: AMED 'nin haftalık oynaklığı ( 1% ) son bir yıldır istikrarlı seyretti.

Şirket Hakkında

KurulduÇalışanlarCEOWeb sitesi
198219,000Richard Ashworthwww.amedisys.com

Amedisys, Inc. iştirakleri ile birlikte Amerika Birleşik Devletleri'nde sağlık hizmetleri sunmaktadır. Üç segmentte faaliyet göstermektedir: Evde Sağlık, Darülaceze ve Yüksek Yoğunluklu Bakım. Evde Sağlık segmenti, hastaların ameliyat, kronik sakatlık veya hastalıktan kurtulmaları için bireylerin evlerinde bir dizi hizmet sunmanın yanı sıra, nitelikli hemşireleri; hemşirelik hizmetleri, fiziksel, konuşma ve mesleki terapide uzmanlaşmış rehabilitasyon terapistleri ve hastalarına yardımcı olmak için sosyal hizmet uzmanları ve yardımcıları aracılığıyla önlenebilir hastane yeniden kabullerini önler.

Amedisys, Inc. Temel Bilgiler Özeti

Amedisys'un kazançları ve gelirleri piyasa değeriyle nasıl karşılaştırılır?
AMED temel i̇stati̇sti̇kler
Piyasa değeriUS$3.32b
Kazançlar(TTM)US$85.63m
Gelir(TTM)US$2.40b
38.8x
F/K Oranı
1.4x
P/S Oranı

AMED aşırı değerli mi?

Gerçeğe Uygun Değer ve değerleme analizine bakınız

Kazanç ve Gelir

En son kazanç raporundan temel karlılık istatistikleri (TTM)
AMED gelir tablosu (TTM)
GelirUS$2.40b
Gelir MaliyetiUS$1.36b
Brüt KârUS$1.04b
Diğer GiderlerUS$952.04m
KazançlarUS$85.63m

Son Raporlanan Kazançlar

Jun 30, 2025

Sonraki Kazanç Tarihi

n/a

Hisse başına kazanç (EPS)2.60
Brüt Marj43.19%
Net Kâr Marjı3.56%
Borç/Özkaynak Oranı26.4%

AMED uzun vadede nasıl bir performans gösterdi?

Geçmiş performansı ve karşılaştırmayı görün

Şirket Analizi ve Finansal Veri Durumu

VeriSon Güncelleme (UTC saati)
Şirket Analizi2025/08/14 17:37
Gün Sonu Hisse Fiyatı2025/08/14 00:00
Kazançlar2025/06/30
Yıllık Kazançlar2024/12/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

PaketVeriZaman ÇerçevesiÖrnek ABD Kaynağı *
Şirket Finansalları10 yıl
  • Gelir tablosu
  • Nakit akış tablosu
  • Bilanço
Analist Konsensüs Tahminleri+3 yıl
  • Finansal tahminler
  • Analist fiyat hedefleri
Piyasa Fiyatları30 yıl
  • Hisse senedi fiyatları
  • Temettüler, Bölünmeler ve Eylemler
Sahiplik10 yıl
  • En büyük hissedarlar
  • İçeriden öğrenenlerin ticareti
Yönetim10 yıl
  • Liderlik ekibi
  • Yönetim Kurulu
Önemli Gelişmeler10 yıl
  • Şirket duyuruları

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntılarına GitHub sayfamızdan ulaşabilirsiniz, ayrıca raporlarımızı nasıl kullanacağınızı anlatan kılavuzlarımız ve Youtube'da eğitim videolarımız da bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.

Analist Kaynakları

Amedisys, Inc. 16 Bu analistlerden 7, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

AnalistKurum
Matthew GillmorBaird
Steven ValiquetteBarclays
Sarah JamesBarclays